Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Erytech Pharma S.A. (ERYP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 6-K Quarterly results
10/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration",
"PHAXIAM Receives Compliance Notice from Nasdaq"
09/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL",
"PHAXIAM Provides Business and Financial Update For the First Half of 2023"
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PHAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten existing shares with a par value of ten-euro cents for one new share with a par value of one euro Publication of the reverse share split notice in the BALO: July 31st , 2023 Start of the reverse share split: August 16 th , 2023 Effective date of the reverse share split : September 18 th , 2023 Lyon and Cambridge , July 27 th , 2023 - PHAXIAM Therapeutics , today announces the implementation of the reverse share split of the shares composing the Company's share capital, by decision of the Chief Executive Officer on July 27 th , 2023, following the sub-delegation granted by the Board of Directors on June 23rd , 2023, taken in accordance with the twenty-third extraordinary resolution ..."
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM"
06/29/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Responds to Akkadian’s Disinformation"
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023"
05/24/2023 F-X Form F-X - Appointment of Agent for Service of Process and Undertaking:
05/24/2023 CB Form CB - Tender Offer/Rights Offering Notification Form:
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Document d'exemption (English translation)",
"PHERECYDES 2022 Annual Financial Report (English translation)"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Update on the Announced Combination with PHERECYDES"
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business and Financial Update for the First Quarter of 2023"
04/18/2023 6-K Quarterly results
03/28/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022"
12/23/2022 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 7.4% stake in ERYTECH Pharma S.A.
11/22/2022 6-K Quarterly results
10/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Announces Receipt of Nasdaq Notice"
09/12/2022 6-K/A Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL"
08/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Regulatory Update"
06/30/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/28/2022 6-K Quarterly results
05/25/2022 6-K Quarterly results
05/13/2022 6-K Quarterly results
05/02/2022 6-K Quarterly results
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Asset Purchase Agreement",
"Asset Purchase Agreement"
04/27/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent"
03/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021"
02/14/2022 SC 13G ARMISTICE CAPITAL, LLC reports a 9.3% stake in ERYTECH Pharma S.A.
02/14/2022 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 16.5% stake in ERYTECH Pharma S.A.
02/10/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy